相关实验视频

Updated: Mar 9, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

塞马格卢提德通过向CPNE1来增强自和溶酶体功能,从而减轻糖尿病血管化

Shengjue Xiao¹, Wei Li^2,3, Naifeng Liu⁴

¹The Department of Geriatrics, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, Jiangsu, China.

Apoptosis : an international journal on programmed cell death

|March 7, 2026

概括

塞马格卢提德通过抑制CPNE1-介导的自来减少糖尿病血管化中的沉积. 这表明塞马格卢提德是预防糖尿病血管并发症的潜在治疗方法.

科学领域:

心血管生物学心血管生物学
内分泌学在内分泌学.
分子医学是分子医学.

背景情况:

糖尿病血管化 (DVC) 会增加死亡率和残疾.
作为GLP-1受体激动剂的塞马格卢提德 (semaglutide) 对心血管有好处,但其对DVC的影响尚不清楚.

研究的目的:

为了研究塞马格卢提德对糖尿病人血管化的作用.
阐明潜在的机制,包括自和CPNE1的参与.

主要方法:

在动物模型和小鼠大动脉光滑肌细胞 (MOVAS) 中使用塞马格卢提德的剂量依赖治疗.
对沉积,RUNX2,BMP2和与自相关的蛋白质 (LC3-II,P62,CTSD,CTSB,LAMP1,LAMP2) 的分析.
通过生物信息学和西方医学评估 lysosomal 功能和 CPNE1 表达.

主要成果:

根据塞马格卢提德的剂量,减少沉积,并降低RUNX2和BMP2.
在AGE-BSA刺激的MOVAS中,塞马格卢提德改善了受损的溶酶体功能,并阻止了自流.
通过恢复自流和溶酶体功能,与CPNE1下调相关联,塞马格卢提德治疗减轻了AGE-BSA诱导的化.

结论:

塞马格卢提德可以减轻糖尿病血管化.
该机制涉及抑制CPNE1介导的自和恢复 lysosomal 功能.
塞马格卢提德为DVC提供了潜在的治疗策略.

关键词:

自自是一种自的过程.在CPNE1中使用.糖尿病血管化糖尿病血管化塞马格卢提德 (semaglutide) 是一种类型的

更多相关视频

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Insulin Secretory Vesicles

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...